EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Considerations for Streamlining the Pathway Toward Approval of a Cognition Enhancer for Schizophrenia

Keith H Nuechterlein, Michael F Green, Stephen R Marder iD

Schizophrenia Bulletin · 2025

DOI: 10.1093/schbul/sbae190 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Schizophrenia Bulletin, 2025. Verfasst von Keith H Nuechterlein und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095-…. Hauptthemen laut MEDLINE: Schizophrenia, Nootropic Agents, Cognitive Dysfunction, Research Design. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the difficulties of developing cognitive enhancers for schizophrenia and demonstrating their efficacy, we welcome a review of the measurement procedures and the clinical trial design recommendations developed through the collaboration of academics, industry, National Institute of Mental Health (NIMH), and U.S.A. Food and Drug Administration (FDA) representatives during the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) process. We provide a perspective from investigators who helped to lead the MATRICS initiative. We acknowledge some of the practical challenges in the use of the MATRICS Consensus Cognitive Battery (MCCB) while pointing out that others are overstated. We suggest that a brief MCCB might be used in phase III trials when phase II results had shown no negative impact on any MCCB cognitive domain. The complexities of requiring a functional co-primary measure are discussed. For clinical trial research design to evaluate monotherapies that might have both antipsychotic and cognition-enhancing properties, we agree that the original MATRICS design recommendations may need to be revised, as those recommendations focused on the evaluation of potential adjunctive cognitive enhancers. Horan et al provide a thoughtful summary of the current challenges in obtaining approval for a new drug designed to enhance cognition in schizophrenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaNootropic AgentsCognitive DysfunctionResearch DesignDrug ApprovalClinical Trials as TopicHumansUnited StatesNational Institute of Mental Health (U.S.)United States Food and Drug Administration

Stichwörter der Autor:innen

FDAMATRICSapprovalcognitionenhancerspathwayschizophreniastreamlining

Substanzen

Nootropic Agents

Autor:innen und Institutionen

  • Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095-6968, United States.
  • Department of Psychology, UCLA, Los Angeles, CA 90095-1563, United States.
  • VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, United States.

ORCID-Profile: Stephen R Marder

Zitieren

APA

Nuechterlein, K. H., Green, M. F., & Marder, S. R. (2025). Considerations for Streamlining the Pathway Toward Approval of a Cognition Enhancer for Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbae190

Vancouver

Nuechterlein KH, Green MF, Marder SR. Considerations for Streamlining the Pathway Toward Approval of a Cognition Enhancer for Schizophrenia. Schizophrenia Bulletin. 2025. doi:10.1093/schbul/sbae190

BibTeX
@article{Nuechterlein2025,
  author = {Nuechterlein, Keith H and Green, Michael F and Marder, Stephen R},
  title = {Considerations for Streamlining the Pathway Toward Approval of a Cognition Enhancer for Schizophrenia},
  journal = {Schizophrenia Bulletin},
  year = {2025},
  doi = {10.1093/schbul/sbae190}
}
Kostenlos starten →